检验医学与临床Issue(24)：3645-3647,3.DOI:10.3969/j.issn.1672-9455.2015.24.013
维格列汀对糖尿病肾病保护作用机制探讨
Investigation of protection mechanism of vildagliptin to diabetic nephropathy
摘要
Abstract
Objective To study the role of CTGF and VEGF in the occurrence and development of rat diabetic nephropathy ,and to investigate the protection mechanism of vildagliptin to diabetic nephropathy .Methods 60 rats were divided into three groups :group A ,B and C .Group A and B were treated by streptozotocin for the preparation of diabetic nephropathy rat models .Then the diabetic nephropathy rats of group A and B were treated by continuous intragastric administration of 8 mg/(kg · d) vildagliptin for 8 and 12 weeks respectively .Group C was control group , and just given intragastric administration of saline .The rats were killed ,then blood glucose ,24 h urine protein ,and the expression levels of CTGF and VEGF of rats in group A and B were detected .Furthermore ,kidney weight index , morphological observation of glomerular volume ,glomerular basement membrane changes were determinated as well as the glomerular average sectional area (MGA) and the average calculated glomerular volume (MGV) were com‐pared .Results The levels of blood glucose ,24 h urine protein ,CTGF and VEGF of group A and B were significantly higher than those of control group .After vildagliptin treatment ,the levels of blood glucose ,24 h urine protein ,CTGF and VEGF reduced in both of group A and B ,and those in group B reduced more significantly than group A .At the same time ,both of the kidney weight index and the degree of renal hypertrophy reduced after treatment ,and the lev‐els of CTGF and VEGF were positively correlated before and after treatment .Conclusion CTGF and VEGF could serve as a valuable indexes of diabetic nephropathy .Vildagliptin might play a role of renal protection via partially reg‐ulate the expression of CTGF and VEGF .关键词
糖尿病肾病/结缔组织生长因子/血管内皮生长因子/维格列汀Key words
diabetic nephropathy/CTGF/VEGF/vildagliptin引用本文复制引用
武红梅,邓丽萍,胡园园,龙爱梅,黄莹,黄震,沈明静..维格列汀对糖尿病肾病保护作用机制探讨[J].检验医学与临床,2015,(24):3645-3647,3.基金项目
广东省深圳市龙岗区科技发展资金2013年度课题资助项目（YS2013075）。 （）
